Company intelligence / Profile preview

Panmira Pharmaceuticals

San Diego, California, United States

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Both AM211 and AM461 (small molecule CRTH2 antagonists) demonstrated dose proportional pharmacodynamic effects and good safety in Phase 1 trials, and were prepared for Phase 2 exploration in asthma and related indications.

Therapeutic areas: ImmunologyPulmonologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Amira Pharmaceuticals (legacy)Bristol Myers Squibb (legacy association)

Beyond the preview

Go deeper on Panmira Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panmira Pharmaceuticals.

Explore the full profile